Tech Company Financing Transactions
Intercept Pharmaceuticals Funding Round
On 8/13/2012, Intercept Pharmaceuticals received $30 million in Series C funding from OrbiMed, Genextra S.p.A. and private investors.
Transaction Overview
Company Name
Announced On
8/13/2012
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Proceeds Purpose
This financing allows us to continue advancing our lead compound OCA in POISE, our Phase 3 PBC trial, while pursuing other therapeutic indications of interest.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10 Hudson Yards 37th Floor
New York, NY 10001
USA
New York, NY 10001
USA
Phone
Undisclosed
Website
Email Address
Overview
For 11 years, Intercept has researched and developed a novel nuclear receptor (FXR). Find out how this science applies to liver and metabolic conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Pruzanski
Chief Financial Officer
Sandip Kapadia
Chief Operating Officer
Jerome Durso
President
Lisa Bright
VP - General Counsel
Ryan Sullivan
VP - Human Resources
David Ford
VP - R & D
Christian Weyer
Browse more venture capital transactions:
Prev: 8/13/2012: SolFocus venture capital transaction
Next: 8/13/2012: BrightWhistle venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs